Related Experiment Video
Updated: Mar 22, 2026

Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations
Published on: October 20, 2017
Pulmonary Arteriovenous Fistula with Pulmonary Hypertension - To Close or Not to Close?
Chiau-Suong Liau1, Jong-Kai Hsiao2, I-Tseng Chu3
1Cardiology Section, Department of Internal Medicine;
Unlabelled:
A 37-year-old female presented to our facility suffering from exertional dyspnea for 2-3 months. Her chest x-ray showed a nodular shadow in the right lower lung, and chest CT revealed a pulmonary arteriovenous fistula (PAVF). Subsequent echocardiographic examination detected no intra-cardiac shunt but did indicate pulmonary hypertension as evidenced by a tricuspid regurgitation flow velocity of 4.17 M/sec. Contrast echocardiography with antecubital vein injection of agitated normal saline demonstrated visualization of the left heart chambers compatible with PAVF. At cardiac catheterization, pulmonary arterial pressure was 59/26 mmHg, mean 34 mmHg. Because there was no intra-cardiac communication detected, primary pulmonary hypertension was tentatively diagnosed. Pulmonary angiography demonstrated a PAVF arising from the lower right pulmonary artery, forming a secular structure on its course in draining into the left atrium through a long pulmonary vein. In this particular anomaly, a concurrence of PAVF with pulmonary hypertension, we judged that the PAVF might serve as a safety valve for pulmonary hypertension and should not be closed. We therefore left the PAVF untreated and thereafter provided medical management for this patient. The concomitant presence of PAVF and pulmonary hypertension is a rare clinical condition. The ultimate treatment strategy for this uncommon condition should be carefully considered.
Key Words:
Computed tomography; Contrast echocardiography; Pulmonary angiography; Pulmonary arteriovenous fistula; Pulmonary hypertension.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

